1390PDose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI